microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Tay KJ, Moul JW, Armstrong AJ. Management of prostate cancer in the elderly. Clin Geriatr Med. 2016;32(1):113–132.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524–531.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Pu Y-S, Chiang HS, Lin CC, et al. Changing trends of prostate cancer in Asia. Aging Male. 2004;7(2):120–132.
   PubMedGoogle Scholar
• Perdana NR, Mochtar CA, Umbas R, et al. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones. 2016;48(3):228–238.
   PubMed Web of Science ®Google Scholar
• Gasnier A, Parvizi N. Updates on the diagnosis and treatment of prostate cancer. Br J Radiol. 2017;90(1075):20170180.
   PubMed Web of Science ®Google Scholar
• Gray BP, Kelly L, Ahrens DP, et al. Tunable cytotoxic aptamer–drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci; 2018;115(18):201717705.
   Web of Science ®Google Scholar
• Awasthi R, Rathbone MJ, Hansbro PM, et al. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology. Drug Delivery Trans Res. 2018;8(1):97–110.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorshid HRK, Fard SS, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen G, He J, et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer. Bioengineered. 2021;Dec;12(1):325–340.
   PubMed Web of Science ®Google Scholar
• Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015 Feb;35(1):3–11.
   PubMed Web of Science ®Google Scholar
• Liang J, Zhang S, Wang W, et al. Long non-coding RNA DSCAM-AS1 contributes to the tumorigenesis of cervical cancer by targeting miR-877-5p/ATXN7L3 axis. Biosci Rep. 2019;40(1):BSR20192061.
   Google Scholar
• Pafundi PC, Caturano A, Franci G. Comment on: miR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(14):4401–4402.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu L, Zhao W, et al. LncRNA SNHG16 promotes the progression of laryngeal squamous cell carcinoma by mediating miR-877-5p/FOXP4 axis. Onco Targets Ther. 2020;13:4569–4579.
   PubMed Web of Science ®Google Scholar
• Zhu S, Deng Y, Gao H, et al. miR‐877‐5p alleviates chondrocyte dysfunction in osteoarthritis models via repressing FOXM1. J Gene Med. 2020;22(11):e3246.
   PubMed Web of Science ®Google Scholar
• Wu K, Yu Z, Tang Z, et al. miR-877-5p suppresses gastric cancer cell proliferation through targeting FOXM1. Onco Targets Ther. 2020;13:4731–4742.
   PubMed Web of Science ®Google Scholar
• Hasan D, Gamen E, Abu Tarboush N, et al. PKM2 and HIF-1α regulation in prostate cancer cell lines. PloS One. 2018;13(9):e0203745.
   PubMed Web of Science ®Google Scholar
• Xu N, Li AD, Ji LL, et al. miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q. Eur J Histochem. 2019 May 3;63(2):3008.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yuan D, Zhou L, et al. Transducin-like enhancer of Split-1 inhibits malignant behaviors in vitro and predicts a better prognosis in pancreatic ductal adenocarcinoma. Front Oncol. 2020;10:576.
   PubMed Web of Science ®Google Scholar
• Ju H, Li Y, Xing X, et al. Manganese-12 acetate suppresses the migration, invasion, and epithelial-mesenchymal transition by inhibiting Wnt/β-catenin and PI3K/AKT signaling pathways in breast cancer cells. Thorac Cancer. 2018 Mar;9(3):353–359.
   Google Scholar
• Tian L, Zhao Z, Xie L, et al. MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget. 2018 Jan 12;9(4):4886–4896.
   PubMedGoogle Scholar
• Zhao Y, Song Y, Yao L, et al. Circulating microRNAs: promising Biomarkers involved in several cancers and other diseases. DNA Cell Biol. 2017;36(2):77.
   PubMed Web of Science ®Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130–6135.
   PubMed Web of Science ®Google Scholar
• Zoni E, van der Horst G, van de Merbel AF, et al. miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α6-integrin expression. Cancer Res. 2015;75(11):2326–2336.
   PubMed Web of Science ®Google Scholar
• Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and mRNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68(15):6162–6170.
   PubMed Web of Science ®Google Scholar
• Du L, Gao Y. PGM5-AS1 impairs miR-587-mediated GDF10 inhibition and abrogates progression of prostate cancer. J Transl Med. 2021;19(1):12.
   PubMed Web of Science ®Google Scholar
• Bhagirath D, Liston M, Akoto T, et al. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients. Sci Rep. 2021 Apr 15;11(1):8279.
   PubMed Web of Science ®Google Scholar
• Guo T, Wang W, Ji Y, et al. LncRNA PROX1-AS1 facilitates gastric cancer progression via miR-877-5p/PD-L1 axis. Cancer Manag Res. 2021; 13:2669–2680.
   Google Scholar
• Yuyu L, Shikun Z, Zhenyu Z, et al. MiR-877-5p targets PDK-1 to promote aspirin-induced apoptosis in gastric mucosal cells. Pharmazie. 2021 Jun 1;76(6):256–260.
   PubMed Web of Science ®Google Scholar
• Wu T, Sun Y, Sun Z, et al. Hsa_circ_0042823 accelerates cancer progression via miR-877-5p/FOXM1 axis in laryngeal squamous cell carcinoma. Ann Med. 2021 Dec;53(1):960–970.
   PubMed Web of Science ®Google Scholar
• Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. BBA - Rev Cancer. 2007;1775(1):92–102.
   PubMed Web of Science ®Google Scholar
• Gu C, Cheng H, Yang H, et al. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia. 2018;30(4):873.
   Web of Science ®Google Scholar
• Pilarsky C, Wenzig M, Specht T, et al. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6(6):744–750.
   PubMed Web of Science ®Google Scholar
• Halasi M, Gartel AL. FOX(M1) news–it is cancer. Mol Cancer Ther. 2013;12(3):245–254.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
   PubMed Web of Science ®Google Scholar
• Kim MY, Jung AR, Kim GE, et al. High FOXM1 expression is a prognostic marker for poor clinical outcomes in prostate cancer. J Cancer. 2019;10(3):749–756.
   PubMed Web of Science ®Google Scholar